| gap-debate-20260410- | Does CSF sTREM2 accurately reflect tissue-level microglial activation states in | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | biomarkers |
| gap-debate-20260410- | What biomarker thresholds reliably predict the optimal timing to switch from TRE | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can biased TREM2 agonists selectively activate DAP12-SYK-PI3K without triggering | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What are the optimal sleep restoration protocols for reversing established tau a | open | 0.80 | 0.00 | 2026-04-10 | 0 | | therapeutics |
| gap-debate-20260410- | How do circadian clock gene variants modify individual susceptibility to sleep-r | open | 0.75 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-debate-20260410- | Which specific glymphatic clearance mechanisms are most therapeutically tractabl | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroscience |
| gap-debate-20260410- | What are the optimal timing and duration parameters for sleep interventions to m | open | 0.75 | 0.00 | 2026-04-10 | 0 | | therapeutics |
| gap-debate-20260410- | Can sleep restoration interventions halt or reverse established tau pathology in | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | clinical-neuroscience |
| gap-debate-20260410- | How do circadian rhythm disruptions mechanistically impair glymphatic clearance | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroscience |
| gap-debate-20260410- | What is the temporal sequence of sleep disruption versus amyloid-beta accumulati | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the temporal dynamics of microglial state transitions during neurodegen | open | 0.75 | 0.00 | 2026-04-10 | 0 | | disease-progression |
| gap-debate-20260410- | How do disease-specific microenvironments in AD, PD, and ALS influence microglia | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | Which pharmacological targets can reliably shift microglia from inflammatory to | open | 0.85 | 0.00 | 2026-04-10 | 0 | | drug-discovery |
| gap-debate-20260410- | What are the molecular signatures that distinguish protective vs. harmful microg | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What experimental designs can validate aging-neurodegeneration hypotheses from e | open | 0.75 | 0.00 | 2026-04-10 | 0 | | experimental-design |
| gap-debate-20260410- | How do species differences affect translation of aging brain gene expression pat | open | 0.80 | 0.00 | 2026-04-10 | 0 | | comparative-biology |
| gap-debate-20260410- | Which aging-related molecular pathways are druggable targets for neurodegenerati | open | 0.85 | 0.00 | 2026-04-10 | 0 | | drug-discovery |
| gap-debate-20260410- | What specific gene expression signatures in aging mouse brain predict human AD v | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do microglial activation states influence tau propagation versus clearance d | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroimmunology |
| gap-debate-20260410- | What synaptic receptor mechanisms mediate tau uptake during trans-synaptic trans | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroscience |
| gap-debate-20260410- | Which extracellular vesicle subtypes are the primary carriers of pathological ta | open | 0.82 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | What are the specific molecular determinants that govern tau strain selection du | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What validation strategies can confirm mouse-derived aging-neurodegeneration hyp | open | 0.75 | 0.00 | 2026-04-10 | 0 | | translational-research |
| gap-debate-20260410- | Which aging-related gene expression changes represent causal drivers versus cons | open | 0.80 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What computational frameworks can effectively predict neurodegenerative vulnerab | open | 0.85 | 0.00 | 2026-04-10 | 0 | | computational-biology |
| gap-debate-20260410- | How can Allen Aging Mouse Brain Atlas data be systematically cross-referenced wi | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What temporal dynamics of gene expression changes distinguish normal aging from | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | systems-neuroscience |
| gap-debate-20260410- | Which aging-associated molecular pathways are causally linked to neurodegenerati | open | 0.85 | 0.00 | 2026-04-10 | 0 | | aging-biology |
| gap-debate-20260410- | How do cross-species differences affect translation of aging brain gene expressi | open | 0.80 | 0.00 | 2026-04-10 | 0 | | comparative-neurobiology |
| gap-debate-20260410- | What specific gene expression signatures in aging mouse white matter predict hum | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What experimental approaches can validate cell vulnerability predictions from tr | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | experimental-neuroscience |
| gap-debate-20260410- | How can transcriptomic vulnerability signatures be translated into druggable the | open | 0.80 | 0.00 | 2026-04-10 | 0 | | drug-discovery |
| gap-debate-20260410- | What are the molecular mechanisms underlying cell-type-specific vulnerability pa | open | 0.85 | 0.00 | 2026-04-10 | 0 | | molecular-neurobiology |
| gap-debate-20260410- | Which specific cell types show greatest vulnerability in AD based on SEA-AD tran | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What experimental approaches can validate aging-neurodegeneration hypotheses in | open | 0.70 | 0.00 | 2026-04-10 | 0 | | experimental-design |
| gap-debate-20260410- | How do regional brain differences in aging gene expression correlate with AD pat | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the druggable targets among aging-neurodegeneration pathway genes? | open | 0.85 | 0.00 | 2026-04-10 | 0 | | drug-discovery |
| gap-debate-20260410- | Which specific aging-related gene expression changes in mouse brain predict huma | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How should multi-expert scientific debates be structured to prevent analytical f | open | 0.75 | 0.00 | 2026-04-10 | 0 | | research-methodology |
| gap-debate-20260410- | Which cortical dynamics alterations represent viable therapeutic targets in neur | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the specific hippocampal circuit disruptions in neurodegeneration using | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How can circuit-level neurodegeneration mechanisms be identified without complet | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | research-methodology |
| gap-debate-20260410- | What determines the selectivity and timing of T-cell infiltration across differe | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuroimmunology |
| gap-debate-20260410- | Which astrocyte reactivity markers predict neuroprotective versus neurotoxic out | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the specific downstream effectors linking TREM2 signaling to complement | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | How do different microglial subtypes (DAM vs inflammatory vs homeostatic) transi | partially_addressed | 0.87 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Which downstream TREM2 signaling pathways should be selectively modulated for th | open | 0.75 | 0.00 | 2026-04-10 | 0 | | molecular-neurobiology |
| gap-debate-20260410- | What biomarkers can reliably distinguish beneficial from detrimental TREM2 activ | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | biomarker-development |
| gap-debate-20260410- | How do disease-specific contexts determine whether DAM activation is protective | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | What are the optimal timing windows for TREM2 agonism vs antagonism across disea | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |